The Japan Nuclear Medicine Market was valued at $694.8 Million in 2025 and projected to reach to $1484.4 Million by 2030, representing a compound annual growth rate of 16.4%. Japan's nuclear medicine market is poised for substantial growth through 2030, driven by demographic shifts and disease burden.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Japan's rapidly aging demographic, with over 29% of the population aged 65+, is significantly driving demand for nuclear medicine diagnostics and therapeutics, particularly for cancer and cardiovascular disease management.
Japan's world-class healthcare system and high adoption rate of cutting-edge imaging technologies position it as a leader in nuclear medicine innovation and procedure utilization in Asia.
With a CAGR of 16.4% from 2025 to 2030, Japan's nuclear medicine market is expanding faster than the global average of 15.1%, reflecting increasing clinical adoption and investment.
Rising incidence of cancer and cardiovascular diseases in Japan is accelerating demand for PET/CT scans, SPECT imaging, and targeted radiotherapy treatments across major metropolitan healthcare centers.
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | THERAPEUTIC NUCLEAR MEDICINE (Type) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 15.1% from 2025 to 2030 |
| Largest Segment | DIAGNOSTIC NUCLEAR MEDICINE (Type) |
| Market Size Base Year (Billions) | ~USD 10.4 (2025) |
| Revenue Forecast (Billions) | ~USD 21.01 (2030) |
| Segments Covered | Type |
1 segment dimensions are covered across the global market.
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 50 | 57.8 | 66.8 | 77.3 | 89.4 | 103.4 | 119.5 | 137.9 | 15.6 |
| DIAGNOSTIC & IMAGING CENTERS | 140.2 | 164.8 | 193.9 | 228.2 | 268.5 | 315.7 | 371.1 | 435.5 | 17.6 |
| HOSPITALS | 304.9 | 354 | 411.2 | 477.7 | 554.8 | 644 | 747 | 865.3 | 16 |
| OTHER END USERS | 17.2 | 19.8 | 22.8 | 26.2 | 30.2 | 34.7 | 39.9 | 45.8 | 15 |
| TOTAL | 512.2 | 596.4 | 694.8 | 809.5 | 942.9 | 1097.8 | 1277.4 | 1484.4 | 16.4 |
Japan's nuclear medicine market is valued at USD 694.8 million in 2025 and is projected to reach USD 1,484.4 million by 2030.
Japan's nuclear medicine market is expected to grow at a compound annual growth rate (CAGR) of 16.4% from 2025 to 2030.
Key drivers include Japan's aging population, rising cancer and cardiovascular disease prevalence, advanced healthcare infrastructure, government support for medical innovation, and increased adoption of PET-CT and SPECT imaging technologies.
PET-CT and SPECT imaging modalities are the most widely adopted in Japan, supported by strong healthcare infrastructure and clinical emphasis on early disease detection.
Japan is positioned as a leading Asia Pacific market for nuclear medicine due to its advanced healthcare system, high healthcare spending, aging population, and strong government support for medical innovation.
This study involved four major activities in estimating the size of the nuclear medicine market. Exhaustive secondary research was done to collect information on the market, peer market, and parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across value chains through primary research. The bottom-up approach was employed to estimate the overall market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and sub-segments.
The secondary research process involved the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Some non-exclusive secondary sources include the Organisation for Economic Co-operation and Development (OECD), European Association of Nuclear Medicine (EANM), National Institutes of Health (NIH), World Nuclear Association (WNA), International Atomic Energy Agency (IAEA), Nuclear Regulatory Commission (NRC), Society of Nuclear Medicine and Molecular Imaging (SNMMI), Nuclear Energy Agency (NEA), Australian Nuclear Science and Technology Organisation (ANSTO), Annual Reports, SEC Filings, Investor Presentations, Journals, Publications from Government Sources and Professional Associations, Expert Interviews, and MarketsandMarkets Analysis.
Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the clinical decision support system market. It was also used to obtain important information about the key players and market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations operating in the clinical decision support system market. The primary sources from the demand side included industry experts, consultants, healthcare providers, hospital administration, and government bodies. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends and key market dynamics.

Note 1: Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.
Note 2: Tiers of companies are defined on the basis of their total revenue in 2022; Tier 1: >USD 1 billion, Tier 2: USD 500 million to USD 1 billion, and Tier 3: <USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
|
Report Metric |
Details |
|
Siemens Healthineers |
Sr.Sales Manager |
|
Curium |
General Manager |
|
Cardinal Health |
Product Sales Specialist |
Both top-down and bottom-up approaches were used to estimate and validate the total size of the nuclear medicine market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
After arriving at the overall market size—using the market size estimation processes as explained above—the market was split into several segments and sub-segments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides, in the provider, payer, and other industries.
Radiopharmaceuticals are drugs that contain radionuclide-emitting ionizing radiation and are used in nuclear imaging to diagnose and treat diseases. The nuclear medicine market is bifurcated into diagnostic and therapeutic segments. Radiopharmaceuticals in the diagnostics market are categorized as SPECT and PET, while radiopharmaceuticals in the therapeutics market are categorized as beta emitters, alpha emitters, and brachytherapy isotopes.
MarketsandMarkets offers the following customizations for this market report:
Full forecast, segment splits, and company analysis for all Nuclear Medicine Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report